The
global Next-Generation Sequencing (NGS) Services Market size
is expected to reach USD 2.87 billion by 2025 at a 13.6% CAGR during the
forecast period, according to a new report by Grand View Research, Inc.
Development of NGS technologies has revolutionized gene sequencing in terms of
reproducibility and cost savings.
This
has resulted in introduction of several advancements in NGS technology to
promote its usage in clinical labs and hospitals. Most current innovations in
this field revolve around simplifying usage of seq-technology and making it
more sophisticated. These factors have driven the uptake of NGS services across
various end users.
Conventional
disease testing service providers have broadened their portfolio with a rising
trend of seq-based genetic tests. For example, in October 2014, ARUP
Laboratories collaborated with the Children’s Hospital of Philadelphia (CHOP).
The service provision for NGS-based HLA genotyping, including HLA Class II and
HLA Class I, began in November 2017.
With
rising trend of high throughput sequencing within the pharma and biotech
industry, there is a need for more developments to improve the speed and
convenience of high throughput seq-platforms and simplify workflows. As a
result, companies are focusing on development of solutions to simplify the
amplification and purification of sample and starting input.
In
July 2017, Norgen released the new Small RNA Library Prep Kit for Illumina.
This kit is being developed to generate small RNA libraries and is optimized
for samples with low input RNA (0.5-1ng), such as urine, serum, plasma,
cerebral spinal fluid (CSF), blood, and exosomes.
Browse
Details of Report @ https://www.grandviewresearch.com/industry-analysis/next-generation-sequencing-ngs-services-market
Further key findings from the report suggest:
- Human genome
sequencing services held the largest revenue share owing to greater
penetration of whole genome and whole exome sequencing
- Gene
regulation services, particularly small RNA sequencing and ChIP-seq, is
anticipated to grow at a lucrative pace during the forecast period. Rising
investment in RNA sequencing is driving the growth of gene regulation
services
- Increase in
installation of sequencing platforms is attributive to the larger revenue
share of sequencing services as compared to other workflow steps. High
maintenance and recovery costs of this step have also resulted in greater
revenue generation
- Universities
and other research entities have emerged as prominent end users owing to
growing application of NGS technology for cancer prognosis as well as
diagnosis and major projects taken up by academicians and universities
- North
America dominated the market by revenue in 2017, owing to higher
penetration of the technology in this region and availability of funds to
employ the technique and derive research findings for disease targeting
- Various
prominent players in this market include Illumina, Inc.; Eurofins
Genomics; BGI; and GENEWIZ Germany GmbH. Companies such as GENEWIZ and
Novogene Corporation are engaged in offering NGS services based on
platforms from major NGS developers
- Companies
such as Illumina and BGI, on the other hand, are involved in developing
sequencing instruments and offering services to research entities.
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/
No comments:
Post a Comment